8-K: Marker Therapeutics Enters Manufacturing Agreement with Cell Ready for MT-401 and MT-601 Production

Marker Therapeutics has signed a Master Services Agreement with Cell Ready, a CDMO owned by a company director, to manufacture GMP drug product for its MT-401 and MT-601 therapies.

Summary

• Marker Therapeutics has entered into a Master Services Agreement with Cell Ready, a contract development and manufacturing organization (CDMO) owned by one of its directors, John Wilson.
• The agreement allows Marker to contract with Cell Ready for various products and services through work orders.
• Cell Ready will supply products in accordance with the requirements of each work order.
• The initial term of the agreement is three years and can be extended by mutual agreement.
• The agreement can be terminated for material breach or insolvency of either party.
• The company also entered into Work Order #1 with Cell Ready for GMP drug product for Marker MT-401 and/or MT-601.
• Work Order #1 includes delivery of final drug product, quality control testing, and general support services.
• The total projected cost for services under Work Order #1 is not expected to exceed $750,000.
• These services will cover the anticipated manufacturing costs for the first quarter of 2024.
• Additional work orders are expected for the remainder of 2024.

Sentiment

Score: 7

Explanation: The agreement is a positive step for the company, securing manufacturing capacity, but the related party aspect introduces a minor concern.

Positives

• The agreement secures a manufacturing partner for Marker's key drug candidates, MT-401 and MT-601.
• The initial work order covers manufacturing costs for the first quarter of 2024, providing near-term production capacity.
• The agreement allows for flexibility through work orders, enabling Marker to scale production as needed.
• The three-year term provides a stable manufacturing relationship.

Negatives

• Cell Ready is owned by a director of Marker Therapeutics, which could raise concerns about potential conflicts of interest.
• The agreement is subject to termination for material breach or insolvency, which introduces some risk.

Risks

• The relationship with Cell Ready, being a related party, could be subject to scrutiny.
• The agreement's success depends on Cell Ready's ability to meet product requirements and timelines.
• The company is reliant on Cell Ready for manufacturing, which could pose a risk if Cell Ready experiences issues.
• The cost of future work orders is not specified, which could impact future expenses.

Future Outlook

Additional work orders are expected to be generated for the remainder of 2024, indicating ongoing manufacturing needs.

Management Comments

• Juan Vera, President and Chief Executive Officer, signed the report on behalf of Marker Therapeutics.

Industry Context

This agreement is typical for biotech companies that outsource manufacturing to specialized CDMOs. The fact that the CDMO is related to a director is not unusual but does require careful management of potential conflicts of interest.

Comparison to Industry Standards

• Many biotech companies, such as Kite Pharma and Juno Therapeutics, rely on CDMOs for manufacturing of their cell therapies.
• The use of a related party CDMO is not uncommon, but requires careful oversight to ensure fair pricing and quality.
• The cost of $750,000 for the initial work order is within the expected range for early-stage GMP manufacturing of cell therapies.

Related Party Transactions

• The Master Services Agreement is with Cell Ready, which is owned by John Wilson, a director and shareholder of Marker Therapeutics.

Stakeholder Impact

• Shareholders will likely view this agreement positively as it secures manufacturing for key drug candidates.
• The agreement provides a clear path for the company to produce its therapies.
• The related party aspect may raise some concerns among shareholders.

Next Steps

• Marker Therapeutics will continue to work with Cell Ready under the Master Services Agreement.
• Additional work orders are expected to be generated for the remainder of 2024.

Key Dates

Keywords

Manufacturing, CDMO, GMP, MT-401, MT-601, Contract Manufacturing, Drug Product, Cell Ready, Master Services Agreement